News Brief Seagen inks deal with Dutch biotech to develop and commercialize drug candidate by Charlotte Schubert on September 26, 2022September 26, 2022 at 10:30 am Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech company based in Utrecht, Netherlands. Seagen will pay Lava $50 million… Read More